Skip to main content
Log in

Pathology of Parkinson’s disease

Changes other than the nigrostriatal pathway

  • Published:
Molecular and Chemical Neuropathology

Abstract

In Parkinson’s disease (PD), in addition to degeneration of the nigrostriatal dopaminergic pathway, a variety of neuronal systems are involved, causing multiple neuromediator dysfunctions that account for the complex patterns of functional deficits. Degeneration affects the dopaminergic mesocorticolimbic system, the noradrenergic locus ceruleus (oral parts) and motor vagal nucleus, the serotonergic raphe nuclei, the cholinergic nucleus basalis of Meynert, pedunculopontine nucleus pars compacta, Westphal-Edinger nucleus, and many peptidergic brainstem nuclei. Cell losses in subcortical projection nuclei range from 30 to 90% of controls; they are more severe in depressed and demented PD patients. Most of the lesions are region-specific, affecting not all neurons containing a specific transmitter or harboring Lewy bodies. In contrast to Alzheimer’s disease (AD), subcortical system lesions in Parkinson’s disease appear not to be related to cortical pathology, suggesting independent or concomitant degeneration. The pathogenesis of multiple-system changes contributing to chemical pathology and clinical course of Parkinson’s disease are unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agid Y., Javoy-Agid F., and Ruberg M. (1987) Biochemistry of neurotransmitters in Parkinson’s disease,Movement Disorders 2 (Marsden C. D. and Fahn S. T., eds.), pp. 166–230, Butterworth, London.

    Google Scholar 

  • Agid Y., Graybiel A. M., Ruberg M., Hirsch E., Blin J., Dubois B., and Javoy-Agid F. (1990) The efficacy of levodopa treatment declines in the course of Parkinson’s disease: Do nondopaminergic lesions play a role?Adv. Neurol. 53, 83–100.

    PubMed  CAS  Google Scholar 

  • Albanese A., Altavista M. C., Gozzo S., Rossi P., Colosimo C., Bentivoglio A. R., Rerretta G., Elia M., Monaco V., and Macchi G. (1990) Chronic administration of MPTP to marmosets.Adv. Neurol. 53, 239–249.

    PubMed  CAS  Google Scholar 

  • Albin R. L., Young A. B., and Penney J. B. (1989) The functional anatomy of basal ganglia disorders.Trends Neurosci. 12, 366–374.

    PubMed  CAS  Google Scholar 

  • Alexander G. E., DeLong M. R., and Strick P. L. (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex.Annu. Rev. Neuroscience 9, 357–381.

    CAS  Google Scholar 

  • Allen J. M., Cross A. J., Crow T. J., Javoy-Agid F., Agid Y., and Bloom S. R. (1985) Dissociation of NPY and somatostatin in Parkinson disease.Brain Res. 337, 197–202.

    PubMed  CAS  Google Scholar 

  • Allen J. M., Cross, A. J., Yeats, J. C., Ghatel, M. A., McGregor, G. F., and Close, S. P. (1986) Neuropeptides and dopamine in the marmoset—Effect of treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): An animal model for Parkinson’s disease.Brain 109, 143–157.

    PubMed  Google Scholar 

  • Allen S. J., Dawbarn D., and Wilcock G. K. (1988) Morphometric immunochemical analysis of neurons in the nucleus basalis of Meynert in Alzheimer’s disease.Brain Res. 454, 275–281.

    PubMed  CAS  Google Scholar 

  • Arai H., Kosaka K., and Iizuka R. (1984a) Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer type dementia.J. Neurochem. 43, 388–393.

    PubMed  CAS  Google Scholar 

  • Arai H., Moroji T., and Kosaka K. (1984b) Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer type dementia.Neurosci. Lett. 52, 73–78.

    PubMed  CAS  Google Scholar 

  • Arendt A., Bigl V., and Tennstedt A. (1985) Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical area in Alzheimer’s disease.Neuroscience 14, 1–14.

    PubMed  CAS  Google Scholar 

  • Arendt T., Bigl V., Arendt A., and Tennstedt A. (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease.Acta Neuropathol. (Berl.) 61, 101–108.

    CAS  Google Scholar 

  • Arendt T., Taubert G., Bigl V., and Arendt A. (1988) Amyloid deposition in the nucleus basalis of Meynert complex: A topographic marker for degenerating cell clusters in Alzheimer’s disease.Acta Neuropathol. (Berl.) 75, 226–232.

    CAS  Google Scholar 

  • Arendt T., Zveginsev H. G., and Leontovich T. A. (1986) Dendritic changes in the nucleus basalis of Menyert and in the diagonal band nucleus in Alzheimer’s disease. A quantitative Golgi investigation.Neuroscience 19, 1265–1278.

    PubMed  CAS  Google Scholar 

  • Armstrong D. M., Benzing W. C., Evans J., Terry R. D., Shields D., and Hansen L. A. (1989) Substance P and somatostatin coexist within neuritic plaques: Implications for the pathogenesis of Alzheimer’s disease.Neuroscience 31, 663–671.

    PubMed  CAS  Google Scholar 

  • Bancher C., Lassmann H., Budka H., Jellinger K., Grundke-Iqbal I., Iqbal K., Wiche G., Seitelberger F., and Wisniewski H. M. (1989) Antigenic profile of Lewy bodies: Immunocytochemical evidence for protein phosphorylation and ubiquitination.J. Neuropathol. Exp. Neurol. 48, 81–93.

    PubMed  CAS  Google Scholar 

  • Beal M. F., and Martin J. B. (1986) Neuropeptides in neurological disease.Ann. Neurol. 20, 547–565.

    PubMed  CAS  Google Scholar 

  • Beal M. F., Clevens R. A., and Mazurek M. F. (1988) Somatostatin and neuropeptide Y immunoreactivity in Parkinson’s disease dementia with Alzheimer’s changes.Synapse 2, 463–467.

    PubMed  CAS  Google Scholar 

  • Beal M. F., Mazurek F., Chattha G. K., Svedsen C. N., Bird E. D., and Martin J. B. (1986) Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer’s disease.Ann. Neurol. 20, 282–288.

    PubMed  CAS  Google Scholar 

  • Beal M. F., Mazurek M. F., and Tran V. T. (1985) Somatostatin receptors are reduced in cerebral cortex in Alzheimer’s disease.Science 229, 289–291.

    PubMed  CAS  Google Scholar 

  • Beckstead R. M. (1987) Striatal substance P cell clusters coincide with the high density terminal zones of the discontinuous nigrostriatal dopaminergic projection system in the cat.Neuroscience 20, 557–576.

    PubMed  CAS  Google Scholar 

  • Bender M. B. (1980) Brain control of conjugate horizontal and vertical eye movements.Brain 103, 25–69.

    Google Scholar 

  • Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger, F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical morphological and neurochemical correlations.J. Neurol. Sci. 20, 415–455.

    PubMed  CAS  Google Scholar 

  • Bigl V., Arendt T., Fischer S., Werner M., and Arendt A. (1987) The cholinergic system in aging.Gerontology 33, 172–180.

    PubMed  CAS  Google Scholar 

  • Birkmayer W. and Riederer P. (1985)Die Parkinson-Krankheit 2nd Ed. (Springer, Wien).

    Google Scholar 

  • Birkmayer W. and Riederer P. (1986) Biological aspects of depression in Parkinson’s disease.Psychopathology 19 (Suppl.) 2, 58–61.

    Article  PubMed  Google Scholar 

  • Bissette G., Nemeroff C. R., Decker M. W., Kizer J. S., Agid Y., and Javoy-Agid F. (1985) Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson’s disease.Ann. Neurol. 17, 324–328.

    PubMed  CAS  Google Scholar 

  • Bogerts B., Häntsch J., and Herzer M. (1983) A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics.Biol. Psychiatry 18, 951–969.

    PubMed  CAS  Google Scholar 

  • Bondareff W., Mountjoy C. Q., and Roth M. (1982) Loss of neurons of origin of the adrenergic projections to the cerebral cortex (nucleus locus ceruleus) in senile dementia.Neurology 32, 164–168.

    PubMed  CAS  Google Scholar 

  • Bondareff W., Mountjoy C. Q., Roth M., Rossor M. N., Iversen L. L., Reynolds G. P. and Hauser D. L. (1987) Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease.Alzheimer Dis. Assoc. Disord. 1, 256–262.

    PubMed  CAS  Google Scholar 

  • Bowen D. A. (1990) Treatment of Alzheimer’s disease.Br. J. Psychiatry 157, 327–330.

    PubMed  CAS  Google Scholar 

  • Brooks W. J., Jarvis M. F., and Wagner C. (1989) Astrocytes as a primary locus for the conversion of MPTP into MPP+.J. Neural Transm. 76, 1–12.

    PubMed  CAS  Google Scholar 

  • Burke W. J., Chung H. D., Huang J. S., Grossberg G. T. and Joh T. H. (1988) Evidence for retrograde degeneration of epinephrine neurons in Alzheimer’s disease.Ann. Neurol. 24, 532–536.

    PubMed  CAS  Google Scholar 

  • Candy J. M., Perry R. H., Perry E. K., Irving D., Blessed G., Fairbairn A. F., and Tomlinson, B. E. (1983) Pathological changes in the nucleus basalis of Meynert in Alzheimer’s and Parkinson’s disease.J. Neurol. Sci. 54, 277–289.

    Google Scholar 

  • Candy J. M., Gascoigne A. D., Biggins A., Smith I., Perry R. H., Perry E. K., McDermott J. R., and Edwardson J. E. (1985) Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer’s disease.J. Neurol. Sci. 71, 315–323.

    PubMed  CAS  Google Scholar 

  • Carmichael S. W., Wilson R. J., Brimijoin W. S., Melton L. J., Okazaki J., Yaksh T., Ahlskog J. E., Stoddard S. L., and Tyce G. M. (1988) Decreased catecholamines in the adrenal medulla of patients with parkinsonism.New Engl. J. Med. 319, 254.

    Google Scholar 

  • Cash R., Dennis R., L’Heureux R., Raisman R., Javoy-Agid F., and Scatton B. (1987) Parkinson’s disease and dementia: Norepinephrine and dopamine in locus ceruleus.Neurology 37, 42–46.

    PubMed  CAS  Google Scholar 

  • Chan-Palay V. (1987) Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: Coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia.J. Comp. Neurol. 260, 201–223.

    PubMed  CAS  Google Scholar 

  • Chan-Palay V., Allen Y. S., Lang W., Haesler U., and Polak J. M. (1985) Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer’s type dementia.J. Comp. Neurol 238, 382–390.

    PubMed  CAS  Google Scholar 

  • Chan-Palay V. and Asan E. (1989a) Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression.J. Comp. Neurol. 287, 357–372.

    PubMed  CAS  Google Scholar 

  • Chan-Palay V. and Asan E. (1989b) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of Alzheimer type and in Parkinson’s disease with and without dementia and depression.J. Comp. Neurol. 287, 373–392.

    PubMed  CAS  Google Scholar 

  • Chan-Palay V., Köhler C., Haesler U., Lang W., and Yasargil G. (1986) Distribution of altered hippocampal neurons and axons immunoreactive with antisera against Neuropeptide Y in Alzheimer’s type dementia.J. Comp. Neurol. 248, 360–375.

    PubMed  CAS  Google Scholar 

  • Chan-Palay V., Köhler C., and Höchli M. (1989) Coexistence of somatostatin and neuropeptide Y in the hippocampus of patients with Alzheimer’s and Parkinson’s disease,The hippocampus—New vistas pp. 513–534, A. R. Liss, New York.

    Google Scholar 

  • Chinaglia G., Probst A., and Palacios J. M. (1990) Neurotensin receptors in Parkinson’s disease and progressive supranuclear palsy: An autoradiographic study in basal ganglia.Neuroscience 19, 351–360.

    Google Scholar 

  • Chui H. C., Mortimer J. A., Slager U., Barrow C., Bonareff W., and Webster D. D. (1986) Pathological correlates of dementia in Parkinson’s disease.Arch. Neurol. 43, 991–995.

    PubMed  CAS  Google Scholar 

  • Coles S. K., Iles J. F., and Nicolopoulos-Stournaras S. (1989) The mesencephalic centre controlling locomotion in the rat.Neuroscience 28, 149–157.

    PubMed  CAS  Google Scholar 

  • Constantinidis J., Bouras C., and Vallet P. G. (1988) Neuropeptides in Alzheimer’s and in Parkinson’s disease.Mt. Sinai J. Med. 55, 102–115.

    PubMed  CAS  Google Scholar 

  • Cross A. J., Crow T. J., Ferier I. N., Johnson A. J., Bloom S. R. and Corsellis J. A. N. (1984) Serotonin receptor changes in dementia of the Alzheimer type.J. Neurochem. 43, 1574–1581.

    PubMed  CAS  Google Scholar 

  • Crow T. J., Cross A. J., Cooper S. J., Deakin J. F., Ferrier I. N., Johnson J. A., Joseph M. H., Owen F., Poulter M., and Lofthouse R. (1984) Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides.Neuropharmacology 23, 1561–1569.

    PubMed  CAS  Google Scholar 

  • Curcio C. A. and Kemper T. (1984) Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density.J. Neuropathol. Exp. Neurol. 43, 359–368.

    PubMed  CAS  Google Scholar 

  • D’Amato R. J., Zweig R. M., Whitehouse P. J., Wenk G. L., Singer H. S., Mayeux R., Price D. L., and Snyder S. H. (1987) Aminergic systems in Alzheimer’s disease and Parkinson’s disease.Ann. Neurol. 22, 229–236.

    PubMed  Google Scholar 

  • Davies P. (1988) Neurochemical studies: An update on Alzheimer’s disease.J. Clin. Psychiatry 49 (Suppl.), 23–28.

    PubMed  CAS  Google Scholar 

  • Davies P., Katzman R., and Terry R. D. (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease.Nature 288, 279.

    PubMed  CAS  Google Scholar 

  • Davis G. C., Williams A. C., Markey S. P., Ebert M. H., Reichert C. M., and Kopin I. J. (1979) Parkinsonism secondary to intravenous injection of meperidine analogues.Psychiatr. Res. 1, 249–254.

    CAS  Google Scholar 

  • Dawbarn D., Rossor M. N., Mountjoy C. Q., Roth M., and Emson P. C. (1986) Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in dementia of Alzheimer type.Neurosci. Lett. 70, 154–159.

    PubMed  CAS  Google Scholar 

  • Dickson D. W., Crystal H., Mattiace L. A. (1989) Diffuse Lewy body disease: Light and electron microscopic immunocytochemistry of senile plaques.Acta Neuropathol. (Berl.) 78, 572–584.

    CAS  Google Scholar 

  • Dietl M. M., Probst A., and Palacios J. M. (1987) On the distribution of cholecystokinin receptor binding sites in the human brain. An autoradiographic study.Synapse 1, 169–183.

    PubMed  CAS  Google Scholar 

  • Doucette R., Fisman M., Hachinski V. C., and Mersky H. (1986) Cell loss from the nucleus basalis of Meynert in Alzheimer disease.Can. J. Neurol. Sci. 13, 435–440.

    PubMed  CAS  Google Scholar 

  • Dubois B., Pillon B., Lhermitte F., and Agid Y. (1990) Cholinergic deficiency and frontal dysfunction in Parkinson’s disease.Ann. Neurol. 28, 117–121.

    PubMed  CAS  Google Scholar 

  • Dubois B., Hauw J. J., Ruberg M., Serdaru M., Javoy-Agid F., and Agid Y. (1985) Démence et maladie de Parkinson: Correlations biochimiques et anatomo-cliniquesRev. Neurol. (Paris) 141, 184–193.

    CAS  Google Scholar 

  • Eadie M. J. (1963) The pathology of certain medullary nuclei in parkinsonism.Brain 86, 781–795.

    PubMed  CAS  Google Scholar 

  • Epelbaum J. (1983) Somatostatin in the central nervous system: Physiology and pathological modifications.Progr. Neurobiol. 27, 63–100.

    Google Scholar 

  • Epelbaum J., Javoy-Agid F., Enjalbert A., Krantic S., Kordon C., and Agid Y. (1988) Somatostatin concentrations and binding sites in human frontal cortex are differently affected in Parkinson’s disease associated with dementia and supranuclear palsy.J. Neurol. Sci. 87, 167–174.

    PubMed  CAS  Google Scholar 

  • Epelbaum J., Ruberg M., Moyse E, Javoy-Agid F., Dubois B., and Agid Y. (1983) Somatostatin and dementia in Parkinson’s disease.Brain Res. 278, 376–397.

    PubMed  CAS  Google Scholar 

  • Esiri M. M., Pearson R. C. A., Steele J. E., Bowen D. M., and Powell T. P. S. (1990) A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer’s disease.J. Neurol. Neurosurg. Psychiatry 53, 161–165.

    PubMed  CAS  Google Scholar 

  • Etienne P., Robitaille Y., Wood P., Gauthier S., Nair N. P. V., and Quirion R. (1986) Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer’s disease.Neuroscience 19, 1279–1291.

    PubMed  CAS  Google Scholar 

  • Ezrin-Waters C. and Resch L. (1986) The nucleus basalis of Meynert.Can. J. Neurol. Sci. 13, 8–14.

    PubMed  CAS  Google Scholar 

  • Ferrier I. N. and Leake A. (1990) Peptides in the neocortex in Alzheimer’s disease and aging.Psychoneuroendocrinology 15, 89–96.

    PubMed  CAS  Google Scholar 

  • Foote S. L., Bloom F. E., and Aston-Jones G. (1983) Nucleus locus ceruleus: New evidence of anatomical and physiological specificity.Physiol. Rev. 63, 844–914.

    PubMed  CAS  Google Scholar 

  • Forno L. S. (1986) The Lewy body in Parkinson’s disease.Adv. Neurol. 45, 35–43.

    Google Scholar 

  • Forno L. S. (1990) Neuropathology of MPTP-induced parkinsonism in animals,Abstr., XIth International Congress of Neuropathology, Kyoto, Sept. 2–8, 1990, p. 5.

  • Forno L. S. and Norville R. L. (1979) Ultrastructure of the neostriatum in Huntington’s and Parkinson’s disease.Adv. Neurol. 23, 123–135.

    Google Scholar 

  • Forno L. S., Gardiner R. E., and Eng L. F. (1985) Somatostatin-like immunoreactivity in the human basal ganglia (abstract).J. Neuropathol. Exp. Neurol. 44, 326.

    Google Scholar 

  • Forno L. S., Langston J. W., DeLanney L. E., and Irwin I. (1988) An electron microscopic study of MPTP-induced inclusion bodies in old monkey.Brain Res. 448, 150.

    PubMed  CAS  Google Scholar 

  • Forno L. S., Langston J. W., DeLanney L. E., Irwin I., and Ricaurte G. A. (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.Ann. Neurol. 20, 449–455.

    PubMed  CAS  Google Scholar 

  • Foster N. L., Tamminaga C. A., O’Donohue T. L., Tanimoto K., Bird E. D., and Chase T. N. (1986) Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer’s disease.Neurosci. Lett. 63, 71–75.

    PubMed  CAS  Google Scholar 

  • Francis P. T. and Bowen D. M. (1989) Tacrine, a drug with therapeutic potential for dementia: Postmortem biochemical evidence.Can. J. Neurol. Sci. 16, 504–510.

    PubMed  CAS  Google Scholar 

  • Francis P. T., Bowen D. M., Lowe S. L., Neary D., Mann D. M. A., and Snowden J. S. (1987) Somatostatin content and release measured in cerebral biopsies from demented patients.J. Neurol. Sci. 78, 1–16.

    PubMed  CAS  Google Scholar 

  • Gaspar P. and Gray F. (1984) Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases.Acta Neuropathol. (Berl.) 64, 43–52.

    CAS  Google Scholar 

  • Gaspar P., Berger B., and Lesur A. (1987) Somatostatin 28 and neuropeptide Y innervation in the septal area and related cortical and subcortical structures of the human brain. Distribution, relationship and evidence for different coexistence.Neuroscience 22, 49–73.

    PubMed  CAS  Google Scholar 

  • German D. C., Dubsch M., Askari S., Speciale S. G., and Bowden D. M. (1988a) 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced parkinsonian syndrome, in Macaca fascicularis: Which midbrain dopaminergic neurons are lost?Neuroscience 24, 161–174.

    PubMed  CAS  Google Scholar 

  • German D. C., Manaye K., Smith W. K., Woodward D. J., and Saper C. B. (1989) Midbrain catecholaminergic loss in Parkinson’s disease: Computer visualization.Ann. Neurol. 26, 507–514.

    PubMed  CAS  Google Scholar 

  • German D. C., Manaye K., Smith W. K., White C. L., Woodward D. J., and Mann D. M. A. (1990) Catecholaminergic cell loss in Parkinson’s disease: Computer image,Abstr., XIth International Congress of Neuropathology, Kyoto, Sept. 2–8, 1990, p. 76.

  • German D. C., Walker B. S., Manaye K., Smith W. K., Woodward D. J., and North A. J. (1988b) The human locus coeruleus: Computer reconstruction of cellular distribution.J. Neurosci. 8, 1776–1788.

    PubMed  CAS  Google Scholar 

  • German D. C., White C. L. III, and Sparkman D. R. (1987) Alzheimer’s disease: Neurofibrillary tangles in nuclei that project to the cerebral cortex.Neuroscience 21, 305–312.

    PubMed  CAS  Google Scholar 

  • Gertz H. J., Cervos-Navarro J., and Ewald V. (1987) The septo-hippocampal pathway in patients suffering from dementia of Alzheimer’s type. Evidence for neuronal plasticity?Neurosci. Lett. 76, 228–232.

    PubMed  CAS  Google Scholar 

  • Geula C. and Mesulam M. M. (1989) Cortical cholinergic fibers in aging and Alzheimer’s disease: A morphometric study.Neuroscience 33, 469–481.

    PubMed  CAS  Google Scholar 

  • Gibb W. R. G. (1990) Juvenile parkinsonism, dopa-responsive dystonia and nigrostriatal subdivision,Abstr. XIth International Congress Neuropathology, Kyoto, Sept 2–8, 1990, p. 5.

  • Gibb W. R. G., Fearnley J. M., and Lees A. J. (1990) The anatomy and pigmentation of the human substania nigra in relation to selective neuronal vulnerability.Adv. Neurol. 53, 31–34.

    PubMed  CAS  Google Scholar 

  • Gibb W. R. G., Mountjoy C. Q., Mann D. M. A., and Lees A. J. (1989a) The substantia nigra and ventral tegmental areas in Alzheimer’s disease and Down’s syndrome.J. Neurol. Neurosurg. Psychiatry 52, 193–200.

    PubMed  CAS  Google Scholar 

  • Gibb W. R. G., Terruli M., Lees A. J., Jenner P., and Marsden C. D. (1989b) The evolution of morphological changes in the nervous system of the common marmoset following the acute administration of MPTP.Movement Disord. 4, 53–74.

    PubMed  CAS  Google Scholar 

  • Glowinski J., Michelot R., and Cheramy A. (1980) Role of striatonigral substance P in the regulation of activity of the striatonigral dopaminergic neurones.Neural Peptides and Neuronal Communication (Costa E. and Trabuchi M., eds.), pp. 51–63, Raven, New York.

    Google Scholar 

  • Goto S., Hirano A., and Matsumoto S. (1989) Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson’s disease and striatonigral degeneration.Ann. Neurol. 26, 766–770.

    PubMed  CAS  Google Scholar 

  • Goto S., Hirano A., and Matsumoto S. (1990) Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson’s and Alzheimer’s diseases.Ann. Neurol. 27, 520–527.

    PubMed  CAS  Google Scholar 

  • Goudsmit E., Hofman M. A., Fliers E., and Swaab D. F. (1990) The supraoptic and paraventricular nuclei of the human hypothalamus in relation to sex, and Alzheimer’s disease.Neurobiol. Aging 11, 529–536.

    PubMed  CAS  Google Scholar 

  • Grafe M. R., Forno L. S., and Eng L. F. (1985) Substance P and met-enkephalin immunoreactivity in Parkinson’s, Huntington’s and Alzheimer’s disease.J Neuropathol. Exp. Neurol. 44, 47–59.

    PubMed  CAS  Google Scholar 

  • Graybiel A. M. (1986) Neuropeptides in the basal ganglia,Neuropeptides in Neurologic and Psychiatric Disease (Martin J. B. and Barchas J. eds.), pp. 135–161, Raven, New York.

    Google Scholar 

  • Graybiel A. M. (1989) Dopaminergic and cholinergic systems in the striatum.Neural mechanisms in disorders of movement (Crossman A. and Sambrook M. A., eds.), Libbey, London.

    Google Scholar 

  • Graybiel, A. M., Hirsch E. C., and Agid Y. (1990) The nigrostriatal system in Parkinson’s disease.Adv. Neurol. 53, 17–29.

    PubMed  CAS  Google Scholar 

  • Guiloff, R. J., George R. J. and Marsden D. C. (1980) Reversible supranuclear ophthalmoplegia associated with parkinsonism.J. Neurol. Neurosurg. Psychiatry 43, 352–354.

    Google Scholar 

  • Halliday G. M., Blumbergs P. C., Cotton R. G. H., Blessing W. W., and Geffen L. B. (1990a) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease.Brain Res. 510, 104–107.

    PubMed  CAS  Google Scholar 

  • Halliday G. M., Blumbergs P. C., Cotton R. G. H., Howe P. R. C., Blessing W. W., and Geffen L. B. (1990b) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease.Ann. Neurol. 27, 373–385.

    PubMed  CAS  Google Scholar 

  • Halliday G. M., Gai, W. P., Blessing W. W., and Geffen L. B. (1990c) Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain.Neuroscience 39, 81–96.

    PubMed  CAS  Google Scholar 

  • Hallanger A. E., Levey A. L., Lee H. J., Rye D. B., and Wainer B. H. (1987) The origins of cholinergic and other subcortical afferents to the thalamus in the rat.J. Comp. Neurol. 262, 105–124.

    PubMed  CAS  Google Scholar 

  • Hassler R. (1938) Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus.J. Psychol. Neurol. (Lpz.) 48, 387–476.

    Google Scholar 

  • Hedreen J. C., Struble R. G., Whitehouse P. J., and Price D. L. (1984) Topography of the magnocellular basal forebrain system in human brain.J. Neuropathol. Exp. Neurol. 31, 1–21.

    Google Scholar 

  • Heilig C. W., Knopman D. S., Mastri A. R., and Frey W. (1985) Dementia without Alzheimer pathology.Neurology 35, 762–765.

    PubMed  CAS  Google Scholar 

  • Hertz L. (1989) Is Alzheimer’s disease an anterograde degeneration, originating in the brainstem, and disrupting metabolic and functional interactions between neurons and glial cells?Brain Res. Rev. 14, 335–353.

    PubMed  CAS  Google Scholar 

  • Hirsch E. C., Graybiel A. M., and Agid Y. A. (1988) Melanized dopaminergic neurons are differently susceptible to degeneration in Parkinson’s disease.Nature 334, 345–348.

    PubMed  CAS  Google Scholar 

  • Hirsch E. C., Graybiel A. M., Duyckaerts C., and Javoy-Agid F. (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson’s disease and progressive supranuclear palsy.Proc. Nat. Acad. Sci. USA 84, 5976–5980.

    PubMed  CAS  Google Scholar 

  • Hökfelt T., Millhorn D., Seroogy K., Tsuruo Y., Ceccatelli S., Lindh B., Meister B., Melander T., Schalling M., Bartfai T., and Terenius L. (1987) Coexistence of peptides with classical neurotransmitters.Experientia 43, 768–780.

    PubMed  Google Scholar 

  • Hornykiewicz O. (1975) Parkinson’s disease and its chemotherapy.Biochem. Pharmacol. 24, 1061–1065.

    PubMed  CAS  Google Scholar 

  • Hornykiewicz O. (1989) The neurochemical basis of the pharmacology of Parkinson’s disease,Drugs for the Treatment of Parkinson’s Disease (Calne D. B., ed.),Handbook of Experimental Pharmacology vol. 88, pp. 185–204, Springer, Berlin.

    Google Scholar 

  • Hornykiewicz O., Pifl C., Kish S. J., Shannak K., and Schingnitz G. (1989) Biochemical changes in idiopathic, Parkinson’s disease, aging, and MPTP parkinsonism: Similarities and differences,Parkinsonism and Aging (Calne, D. B., et al., eds.), pp. 57–67, Raven, New York.

    Google Scholar 

  • Hunter S. (1985) The rostral mesencephalon in Parkinson’s and Alzheimer’s disease.Acta Neuropathol. (Berl.) 68, 326–334.

    Google Scholar 

  • Ichimija Y., Arai H., Kosaka K., and Iizuka R. (1986) Morphological and biochemical changes in the cholinergic and monoaminergic system in Alzheimer-type dementia.Acta Neuropathol. (Berl.) 70, 112–116.

    Google Scholar 

  • Imai H., Steindler D. A., and Kitai S. (1987) The organization of divergent axonal projections from the midbrain raphe nuclei in the rat.J. Comp. Neurol. 243, 363.

    Google Scholar 

  • Ingram V. M., Koenig J. H., Miller C. H., Moore H. E., Blanchard B., and Perry D. E. (1987) The locus coeruleus: Computer assisted 3-dimensional analysis of degeneration in Alzheimer’s and Down’s disease,Alzheimer’s Disease: Advances in Basic Research and Therapy (Wurtman R. J., Corkin, S. H., and Growden J. H. eds.), Center for Brain Science and Metabolism Charitable Trust, Cambridge, pp. 435–440.

    Google Scholar 

  • Javoy-Agid F., Hirsch E. C., Dumas S., Duyckaerts C., Mallet J., and Agid Y. (1990) Decreased tysosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson’s disease: An in situ hybridization study.Neuroscience 38, 245–253.

    PubMed  CAS  Google Scholar 

  • Javoy-Agid F., Ploska A., and Agid Y. (1981) Microtopography of tyrosine hydroxylase, glutamic adic decarboxylase and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and parkinsonian brain.J. Neurochem. 37, 1218–1227.

    PubMed  CAS  Google Scholar 

  • Javoy-Agid F., Ruberg M., Taquer H., Bobobza B., and Agid Y. (1984) Biochemical neuropathology of Parkinson’s disease.Adv. Neurol. 40, 189–197.

    PubMed  CAS  Google Scholar 

  • Jellinger K. (1986) Overview of morphological changes in Parkinson’s disease.Adv. Neurol. 45, 1–18.

    Google Scholar 

  • Jellinger K. (1987) The pathology of parkinsonism,Movement Disorders 2 (Marsden C. D. and Fahn St., eds.), pp. 124–165, Butterworth, London.

    Google Scholar 

  • Jellinger K. (1988) The pedunculopontine nucleus in Parkinson’s disease, supranuclear palsy and Alzheimer’s disease.J. Neurol. Neurosurg. Psychiatry 51, 540–544.

    PubMed  CAS  Google Scholar 

  • Jellinger K. (1989) Pathology of Parkinson’s syndrome,Drugs for the Treatment of Pakinson’s Disease (Calne, D. B., ed.), pp. 47–112, Springer, Berlin.

    Google Scholar 

  • Jellinger K. (1990a) Changes in subcortical nuclei in Parkinson’s disease,Function and Dysfunction of the Basal Ganglia (Franks A. J., Ironside J. W., et al., eds.), pp. 69–94, Manchester University Press, Manchester, NY.

    Google Scholar 

  • Jellinger K. (1990b) New developments in the pathology of Parkinson’s diseaseAdv. Neurol. 53, 1–16.

    PubMed  CAS  Google Scholar 

  • Jellinger K. (1990c) Morphology of Alzheimer’s disease and related disorders,Alzheimer’s Disease: Epidemiology, Neurochemistry and Clinics (Beckmann H., Maurer M., Riederer P., eds.),Key Topics in Brain Research, pp. 67–77, Springer, Wien.

    Google Scholar 

  • Jellinger K. and Paulus W. (1990) Bedeutung der Nigraveränderungen bei Parkinson-Syndromen,Parkinson-Krankheit und Nigraprozeß, (Fischer, P.-A., ed.), pp. 3–27 Basle: Ed. Roche.

    Google Scholar 

  • Jenner P. and Marsden C. D. (1990) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): An update on its relevance to the cause and treatment of Parkinson’s disease,Function and Dysfunction of the Basal Ganglia (Franks A. J., et al., eds.), pp. 140–160, Manchester University Press, Manchester, NY.

    Google Scholar 

  • Juncos J. L., Hirsch E. C., Malessa S., Duyckaerts C., Hersh L. B., and Agid Y. (1991) Mesencephalic cholinergic nuclei in progressive supranuclear palsy.Neurology 41, 25–30.

    PubMed  CAS  Google Scholar 

  • Katzman R., Terry R., DeTeresa R., Brown T., Davies P., Fuld P., Renbing X., and Peck A. (1988) Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous cortical plaques.Ann. Neurol. 23, 138–144.

    PubMed  CAS  Google Scholar 

  • Kelly M. and Kowall N. (1989) Corticotropin-releasing factor immunoreactive neurons persist throughout the brain in Alzheimer’s disease.Brain Res. 501, 392.

    Google Scholar 

  • Kish S. J., Shannak K., and Hornykiewicz O. (1988) Uneven patterns of dopamine loss in the striatum of patients with Parkinson’s disease.N. Engl. J. Med. 318, 876–880.

    PubMed  CAS  Google Scholar 

  • Köhler C., Erikson L. G., Davies S., and Chan-Palay V. (1987) Colocalization of neuropeptide tyrosine and somatostatin immunoreactivity in neurons of individual hippocampal subfields in rat.Neurosci. Lett. 78, 1–6.

    PubMed  Google Scholar 

  • Konradi C., Svoma E., Jellinger K., Riederer P., Denney R. M. (1988) Topographic immunocytochemical mapping of monoamine oxidase A, monoamine oxidase B and tyrosine hydroxylase in human postmortem brain stem.Neuroscience 26, 791–802.

    PubMed  CAS  Google Scholar 

  • Kopin I. J. and Schoenberg D. G. (1988) MPTP in animal models of Parkinson’s disease.Mt. Sinai Med. J. 55, 43–49.

    CAS  Google Scholar 

  • Korczyn A. D. (1989) Autonomic nervous system screening in patients with early Parkinson’s disease,Early Diagnosis and Preventive Therapy in Parkinson Disease (Przuntek H. and Riederer P., eds.), pp. 41–48, Springer, Wien-New York.

    Google Scholar 

  • Kowall N. W., and Beal M. F. (1988) Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: Normal anatomy and alterations in Alzheimer’s disease.Ann. Neurol. 23, 105–114.

    PubMed  CAS  Google Scholar 

  • Kubota Y., Inagaki S., and Kito S. (1986) Innervation of substance P neurons by catecholaminergic terminals in the neostriatum.Brain Res. 375, 163–167.

    PubMed  CAS  Google Scholar 

  • Langston J. W. and Irwin I. (1989) Pyridine toxins,Drugs for the treatment of Parkinson’s Disease (Calne D. B., ed.), pp. 205–226., Springer, Berlin-New York.

    Google Scholar 

  • Lewy F. H. (1913) Zur pathologischen Anatomie der Paralysis agitans.Dtsch. Z. Nervenheilk. 50, 50–55.

    Google Scholar 

  • Li S. J., Sivam S. P., McGinty J. F., Huang Y. S. and Hong J. S. (1987) Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway.J. Pharmacol. Exp. Ther. 243, 792–798.

    PubMed  CAS  Google Scholar 

  • Llorens-Cortes C., Javoy-Agid F., Agid Y, Taquet H., and Schwartz J. C. (1984) Enkephalinergic markers in substantia nigra and caudate nucleus from parkinsonian subjects.J Neurochem. 43, 874–877.

    PubMed  CAS  Google Scholar 

  • Loughlin S. E., Foote S. L., and Bloom F. E. (1986) Efferent projections of nucleus locus coeruleus: Topographic organization of cells of origin demonstrated by three-dimensional reconstruction.Neuroscience 18, 291–306.

    PubMed  CAS  Google Scholar 

  • Loew-Hummel P., Gertz H.-J. Ferszt R., and Cervos-Navarro J. (1989) The basal nucleus of Meynert revisited.Arch. Gerontol. Geriatr. 8, 21–27.

    Google Scholar 

  • McGeer E. G., and McGeer P. L. (1989) Biochemical neuroanatomy of the basal ganglia,Drugs for the Treatment of Parkinson’s Disease (Calne D. B., ed.), pp. 112–148,Handbook of Experimental Pharmacology vol. 88, Springer, Wien-New York.

    Google Scholar 

  • McGeer P. L., McGeer E. G., and Suzuki J. (1984) Aging, Alzheimer’s disease, and the cholinergic system in the basal forebrain.Neurology 34, 741–745.

    PubMed  CAS  Google Scholar 

  • Malessa S., Hirsch E. C., Cerver P., Duyckaerts C., and Agid Y. (1990) Catecholaminergic systems in the medulla oblongata in Parkinsonian syndromes. A quantitative immunohistochemical study in Parkinson’s disease, progressive supranuclear palsy, and striatonigral degeneration.Neurology 40, 1739–1742.

    PubMed  CAS  Google Scholar 

  • Maloteaux J. M., Laterre E. C., Ladurot P. M., Javoy-Agid F., and Agid Y. (1988) Decrease of serotonin-R-2 receptors in temporal cortex of patients with Parkinson’s disease and progressive supranuclear palsy.Movement Disord. 3, 255–262.

    PubMed  CAS  Google Scholar 

  • Mann D. M. A. and Yates P. O. (1983) Pathological basis for neurotransmitter changes in Parkinson’s disease.Neuropathol Appl. Neurobiol. 9, 3–19.

    PubMed  CAS  Google Scholar 

  • Mann D. M. A. and Yates P. O. (1986) Neurotransmitter deficits in Alzheimer’s disease and other dementing disorders.Hum. Neurobiol. 5, 147–156.

    PubMed  CAS  Google Scholar 

  • Mann D. M. A., Yates P. O., and Hawkes J. (1983) The pathology of the human locus coeruleus.Clin. Neuropathol. 2, 1–7.

    PubMed  CAS  Google Scholar 

  • Mann D. M. A., Yates P. O., and Marcyniuk B. (1984) Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer’s disease and their relationship to the accumulation of lipofuscin pigment.Mech. Ageing Dev. 25, 189–204.

    PubMed  CAS  Google Scholar 

  • Mann D. M. A., Yates P. O., and Marcyniuk B. (1985a) Correlation between senile plaques and neurofibrillary tangle counts in the cerebral cortex and neuron al counts in cortex and subcortical structures in Alzheimer’s disease.Neurosci. Lett. 56, 51–55.

    PubMed  CAS  Google Scholar 

  • Mann D. M. A., Yates P. O., and Marcyniuk B. (1985b) Changes in Alzheimer’s disease in the magnocellular neurons of the supraoptic and paraventricular nuclei and their relationship to the noradrenergic deficit.Clin. Neuropathol. 4, 127.

    PubMed  CAS  Google Scholar 

  • Mann D. M. A., Yates P. O., and Marcyniuk B. (1987) Dopaminergic systems in Alzheimer’s disease and Down’s syndrome at middle age.J. Neurol. Neurosurg. Psychiatry 50, 341–344.

    PubMed  CAS  Google Scholar 

  • Marcyniuk B., Mann D. M. A., and Yates P. O. (1986) Loss of nerve cells from locus coeruleus in Alzheimer’s disease is topographically arranged.Neurosci. Lett. 64, 247–252.

    PubMed  CAS  Google Scholar 

  • Marcyniuk B., Mann D. M. A., and Yates P. O. (1989) The topography of nerve cell loss from the locus coeruleus in elderly persons.Neurobiol Aging 10, 5–9.

    PubMed  CAS  Google Scholar 

  • Masullo C., Pocchiari M., Mariotti P., Macchi G., Garruto R. M., Gibbs C. J. Jr., et al. (1989) The nucleus basalis of Menyert in Parkinson-dementia of Guam: A morphometric study.Neuropathol. Appl. Neurobiol. 15, 193–206.

    PubMed  CAS  Google Scholar 

  • Matzuk M. M. and Saper C. B. (1985) Preservation of hypothalamic dopaminergic neurons in Parkinson’s disease.Ann. Neurol. 18, 552–555.

    PubMed  CAS  Google Scholar 

  • Mauborgne A., Javoy-Agid F., Legrand J. C., Agid Y., and Cesselin F. (1983) Decrease of substance P-like immunoreactivity in the substantia nigra and palidum of parkinsonian brains.Brain Res. 268, 167–170.

    PubMed  CAS  Google Scholar 

  • Mayeux R. (1990) The “serotonin hypothesis” for depression in Parkinson’s disease.Adv. Neurol. 53, 163–166.

    PubMed  CAS  Google Scholar 

  • Meltzer H. (1989) Serotonergic dysfunction in depression.Br. J. Psychiatry 155, 25–31.

    Google Scholar 

  • Mesulam M. M., and Geula C. (1988) Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase.J. Comp. Neurol. 275, 216–260.

    PubMed  CAS  Google Scholar 

  • Mesulam M. M and Mufson E. J. (1984) Neuronal inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey.Brain 107, 253–274.

    PubMed  Google Scholar 

  • Mitchell I. J., Aambrook M. A., Jackson A., Clarke C. E., Robertson R. G., Boyce S., and Crossman A. R. (1990) Basal ganglia function in experimental movement disorders,Function and Dysfunction in the Basal Ganglia (Franks A. J. et al., eds.), pp. 94–109, Manchester University Press, Manchester, NY.

    Google Scholar 

  • Mizutani T., Aki M., Shiozawa R., Tanabe H. Uchigata M. Oda M., Endo Y., and Hara M. (1991) Clinico-pathologic study of dementia in Parkinson’s disease with special reference to degeneration of the locus ceruleus.Acta Neuropathol. (Berl.) 81, in press.

  • Moossy J., Zubenko G. B., Martinez J., and Rao G. (1988) Bilateral symmetry of morphologic lesions in Alzheimer’s disease.Arch. Neurol. 45, 251–254.

    PubMed  CAS  Google Scholar 

  • Mufson E. J., Mash D., and Hersh L. B. (1988) Neurofibrillary tangles in cholinergic pedunculopontine nucleus in Alzheimer’s disease.Ann. Neurol. 24, 623–629.

    PubMed  CAS  Google Scholar 

  • Mufson E. J., Presley L. N., and Kordower J. H. (1991) Nerve growth factor immunoreactivity with the nucleus basalis (Hc 4) in Parkinson disease. Reduced cell numbers and co-localization with cholinergic neurons.Brain Res. 539, 19–30.

    PubMed  CAS  Google Scholar 

  • Mulligan K. A. and Tork I. (1988) Serotonergic innervation of the cat cerebral cortex.J. Comp. Neurol. 270, 86–110.

    PubMed  CAS  Google Scholar 

  • Nagatsu T. (1990) Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP treated mice.Adv. Neurol. 53, 207–214.

    PubMed  CAS  Google Scholar 

  • Nakano I. and Hirano A. (1984) Neuron loss in the nucleus basalis of Meynert in Parkinson-dementia complex of Guam.Ann. Neurol. 13, 87–91.

    Google Scholar 

  • Nakashima S. and Ikuta F. (1984) Tyrosine hydroxylase proteins in Lewy bodies of parkinsonism and senile brain.J. Neurol. Sci. 66, 91–96.

    PubMed  CAS  Google Scholar 

  • Nemeroff C. B., Kizer J. S., Reynolds G. P., and Bisette G. (1989) Neuropeptides in Alzheimer’s disease: A postmortem study.Regul. Pept. 25, 123–130.

    PubMed  CAS  Google Scholar 

  • Nieuwenhuys R., Voogd J., and Van Huijzen C. (1988)The Human Central Nervous System. A Synopsis and Atlas 3rd Ed., (Springer, Berlin).

    Google Scholar 

  • Olszewski J. and Baxter D. (1982)Cytoarchitecture of the Human Brain Stem 2nd Ed. (Karger, Basel, New York).

    Google Scholar 

  • Palmer A. M., Francis P. T., Bowen D. M., Benton J. S., Neary D., Mann D. M., and Swanson J. S. (1987) Catecholaminergic neurons assessed ante-mortem in Alzheimer’s disease.Brain Res. 414, 365–375.

    PubMed  CAS  Google Scholar 

  • Paulus W. and Jellinger K. (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease.J. Neuropathol Exp. Neurol., in press.

  • Pearson R. C. A., and Powell T. P. S. (1987) Anterograde vs retrograde degeneration of the nucleus basalis medialis in Alzheimer’s disease.J. Neural Transm. (Suppl.) 24, 139–146.

    CAS  Google Scholar 

  • Pearson R. C. A., Sofroniew M. V., Cuello A. C., Powell T. P., Eckenstein, F., Esiri M. M., and Wilcock G. K. (1983) Persistence of cholinergic neurons in the basal nucleus of a brain with senile dementia of the Alzheimer’s type.Brain Res. 289, 375–379.

    PubMed  CAS  Google Scholar 

  • Perry E. K., Smith C. J., Court J. A., and Perry R. H. (1990a) Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types.J Neural Transm. (P-D Sect.) 2, 149–158.

    CAS  Google Scholar 

  • Perry E. K., Smith C. J., Perry R. H., Johnson M., and Fairbairn A. F. (1989) Nicotinic (3H-nicotine) receptor binding in human brain: Characterization and involvement in cholinergic neuropathology.Neurosci. Res. Commun. 5, 117–124.

    CAS  Google Scholar 

  • Perry E. K., Curtis M., Dick D. J., Atack J. H, Bloxham C. A., Blessed G., Fairbairn A., Tomlinson B. E., and Perry R. H. (1985) Cholinergic correlates of cognitive impairment in Parkinson’s disease: Comparison with Alzheimer’s disease.J. Neurol. Neurosurg. Psychiatry 48, 413–421.

    PubMed  CAS  Google Scholar 

  • Perry E. K., Tomlinson B. E., Blessed G., Perry R. H., Cross A. J., and Crow T. J. (1981) Neuropathological and biochemical observations on the noradrenergic system in Alzheimer’s disease.J. Neurol. Sci. 51, 279–287.

    PubMed  CAS  Google Scholar 

  • Perry R. H. (1986) Alzheimer’s disease: Recent advances in neuropathology.Br. Med. Bull. 42, 45–50.

    Google Scholar 

  • Perry R. H., Irving D., Blessed G., Fairbairn A. F., and Perry E. K. (1990b) Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly.J. Neurol. Sci. 95, 119–139.

    PubMed  CAS  Google Scholar 

  • Perry R. H., Tomlinson B. E., Candy J. M., Blessed G., Foster J. F., Bloxham C. A., and Perry E. R. (1983) Cortical cholinergic deficit in mentally impaired Parkinsonian patients.Lancet 2, 311–315.

    Google Scholar 

  • Perry R. H., Perry E. K., Smith C. J., Xuereb J. H., Irving D., Whitford C. A. Candy J. M., and Cross A. J. (1987) Cortical neuropathological and neurochemical substrates of Alzheimer’s and Parkinson’s disease.J. Neural Transm. (Suppl.) 24, 131.

    CAS  Google Scholar 

  • Probst A., Cortex R., Ulrich J., and Palacios J. M. (1988) Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer’s disease: An autoradiographic study.Brain Res. 450, 190–201.

    PubMed  CAS  Google Scholar 

  • Quirion R., Martel J. C., Robitaille Y. Etienne P., Wood P., Nair N. P. V. and Gauthier S. (1986) Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type.Can. J. Neurol. Sci. 13, 503–510.

    PubMed  CAS  Google Scholar 

  • Ransmayer G., Cervera P., Hirsch E. Ruberg M., Hersh L. B., Duyckaerts C., Hauw J. J., Deluneau F., and Agid Y. (1989) Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer’s disease.Neuroscience 32, 701–714.

    Google Scholar 

  • Rascol O., Clanet M., Motastruc J. L., Simonetta M., Soulier-Esteve M. J., Doyon B., and Rascol A. (1989) Abnormal ocular movements in Parkinson’s disease.Brain 112, 1193–1214.

    PubMed  Google Scholar 

  • Reid M. S., Herrera-Marschitz M., Hökfelt T., Lindefors N., Persson H., and Ungerstedt U. (1990) Striatonigral GABA dynorphin, substance P and neurokinin-A modulation of nigrostriatal release. Evidence for direct regulatory mechanisms.Exp. Brain Res. 82, 293–304.

    PubMed  CAS  Google Scholar 

  • Reinikainen R., Paljärvi L., and Huusekonnen M. (1988b) A postmortem study of noradrenergic, serotonergic and GABAergic neurones in Alzheimer’s disease.J. Neurol. Sci. 84, 101–115.

    PubMed  CAS  Google Scholar 

  • Reinikainen K. J., Riekkinen P. J., and Paljärvi L (1988a) Cholinergic deficit in Alzheimer’s disease: A study based on CSF and autopsy data.Neurochem. Res. 13, 135–146.

    PubMed  CAS  Google Scholar 

  • Ricaurte G. A., Irwin I., Forno L. S., DeLanney L. E., Langston E. B., and Langston J. W. (1987) Aging and MPTP-induced degeneration of dopaminergic neurons in the substantia nigra.Brain Res. 403, 43–51.

    PubMed  CAS  Google Scholar 

  • Riederer P., Rausch W. D., Birkmayer W., Jellinger K., and Seeman D. (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies.J. Neural Transm. (Suppl.) 14, 121–133.

    CAS  Google Scholar 

  • Riederer P., Sofic E., Konradi C., Kornhuber J., Beckmann H., Dietl M., Moll G., and Hebenstreit G. (1990) The role of dopamine in the control of neurobiological functions,The Role of Brain Dopamine (Flückinger E., Müller E. E., and Thorner M. O., eds.), pp. 1–17, Springer, Berlin.

    Google Scholar 

  • Rinne J. O., Paljärvi L., and Rinne U. K. (1987) Neuronal size and density in the nucleus basalis Meynert in Alzheimer’s disease.J. Neurol. Sci. 79, 67–76.

    PubMed  CAS  Google Scholar 

  • Rinne J. O., Lönnberg P., Marjamäki P., and Rinne U. K. (1989b) Brain muscarinic receptor subtypes are differentially affected in Alzheimer’s disease and Parkinson’s disease.Brain Res. 483, 402–406.

    PubMed  CAS  Google Scholar 

  • Rinne J. O., Rummukainien J., Paljärvi L., and Rinne U. K. (1989a) Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra.Ann. Neurol. 26, 47–50.

    PubMed  CAS  Google Scholar 

  • Rinne U. K., Rinne J. K., Rinne J. O., Laakso K., Tenovuo L., Lönnberg P., Koskinen V. (1983) Brain enkephalin receptors in Parkinson’s disease.J. Neural Transm. (Suppl.) 19, 163–171.

    CAS  Google Scholar 

  • Rogers J. D., Brogan D., and Mirra S. S. (1985) The nucleus basalis Meynert in neurological disease: A quantitative morphological study.Ann. Neurol. 17, 163.

    PubMed  CAS  Google Scholar 

  • Rossor M. N., Iversen L. I., and Reynolds G. P. (1984) Neurochemical characteristics of early and late onset types of Alzheimer’s disease.Br. Med. J. 288, 961–964.

    CAS  Google Scholar 

  • Ruberg M. and Agid Y. (1988) Dementia in Parkinson’s disease,Handbook of Psychopharmacology, vol. 20 (Iversen L., et al., eds.), Plenum, New York.

    Google Scholar 

  • Ruberg M., Javoy-Agid F., Hirsch E., Scatton B., LHeureux R., Hauw J. J., Duyckaerts C., Gray F., Morel-Maroger A., and Rascol A. (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy.Ann. Neurol. 18, 523–529.

    PubMed  CAS  Google Scholar 

  • Sadoul J. L., Checler F., Kitabki P., Rostene W., Javoy-Agid F., and Vincent J. P. (1984) Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects.Biochem. Biophys. Res. Commun. 125, 395–404.

    PubMed  CAS  Google Scholar 

  • Saper C. B., German D. C., and White C. L. (1985) Neuronal pathology in the nucleus basalis of Meynert and associated cell groups in senile dementia of the Alzheimer’s type. Possible role in cell loss.Neurology 35, 1089–1095.

    PubMed  CAS  Google Scholar 

  • Scarnati E., Gasbarri A., Campana E., and Pacitti C. (1987) The organization of the nucleus tegmenti pedunculopontine neurons projecting to basal ganglia and thalamus.Neurosci. Lett. 79, 11–16.

    PubMed  CAS  Google Scholar 

  • Scatton B., Dennis T., L’Heureux R., Montofort J., Duyckaerts C., and Javoy-Agid F. (1986) Degeneration of noradrenergic and serotonergic but not dopaminergic neurons in lumbar spinal cord of parkinsonian patients.Brain Res. 380, 181–185.

    PubMed  CAS  Google Scholar 

  • Schneider J. S., Yuwiler A., and Markham C. H. (1987) Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.Brain Res. 411, 144–150.

    PubMed  CAS  Google Scholar 

  • Shin R.-W., Kitamoto T., and Tateishi J. (1991) Modified tau is present in younger nondemented persons: A study of subcortical nuclei in Alzheimer’s disease and progressive supranuclear palsy.Acta Neuropathol. (Berl.) 81, in press.

  • Sirvio J., Rinne J. O., Valjakka A., Rinne U. K., Riekkinen P. J., and Paljärvi L. (1989) Different forms of brain acetylcholinesterase and muscarinic binding in Parkinson’s disease.J. Neurol. Sci. 90, 23–32.

    PubMed  CAS  Google Scholar 

  • Sofic E., Moll G., Riederer P., Jellinger K., and Gabriel E. (1988) Monoaminerge Läsion bei seniler Demenz vom Alzheimer-Typ (SDAT).Biologische Psychiatrie. Synopsis 1986/87 (Beckmann H., and Laux G., eds.), pp. 151–157, Springer, Berlin.

    Google Scholar 

  • Sparks D. L., DeKosky S. T., and Markesberry W. (1988) Alzheimer’s disease. Aminergic-cholinergic alterations in hypothalamus.Arch. Neurol. 45, 994–999.

    PubMed  CAS  Google Scholar 

  • Steinbush H. W. M. (1984) Serotonin-immunoreactive neurons and their projections in the CNS,Handbook of Chemical Neuroanatomy, vol. 3: Classical Transmitters and Transmitter Receptors in CNS, Part II (Björklund A., Hökfelt T., and Kuhar M. J., eds.), pp. 68–125, Elsevier, Amsterdam-New York.

    Google Scholar 

  • Steriade M. and Biesold D. (1990)Brain Cholinergic Systems, Oxford University Press.

  • Studler J. M. and Javoy-Agid F. (1985) Cholecystokinin octapeptide immunoreactivity distribution in human brain.Ann. NY Acad. Sci. 448, 656–659.

    Google Scholar 

  • Swaab D. F., Fliers E., and Goudsmit E. (1986) Differential cell loss in (peptide) neurons in the anterior hypothalamus with aging and Alzheimer’s disease,Neurology (Poeck K., Freund H. J., Gänshirt H., eds.), p. 119–125, Springer.

  • Swanson L. W. (1982) Normal hippocampal circuitry.Neurosci. Res. Progr. Bull. 9, 624–637.

    Google Scholar 

  • Tabaton M., Schenone A., Romagnoli P., and Mancardi G. L. (1985) A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer’s disease.Acta Neuropathol. (Berl.) 68, 218–223.

    CAS  Google Scholar 

  • Tagliavini F. and Pilleri G. (1984) The basal nucleus of Meynert in cerebral aging and degenerative dementias,Brain Pathology (Tagliavini F. and Pilleri G., eds.), The basal nucleus of Meynert in cerebral aging and degenerative dementias,Brain Pathology (Tagliavini F. and Pilleri G., eds.), vol. 1, pp. 181–218. Bern.

  • Tagliavini F., Pilleri G., Bouraas C., and Constantinidis J. (1984) The nucleus basalis of Meynert in cerebral aging and degenerative dementias,Brain Pathology (Tagliavini F., and Pilleri G., eds.) pp. 181–218. Bern.

  • Taquet H., Javoy-Agid F., Giraud P., Legrand J. D., Agid Y., and Cesselin F. (1985) Dynorphin levels in parkinsonian patients.Brain Res. 341, 390–392.

    PubMed  CAS  Google Scholar 

  • Taquet H., Nomoto M., Rose S., Jenner P., Javoy-Agid F., Mauborgne A., Benoliel J. J., Marsden C. D., Legrand J. C., Agid Y., Hamon M., and Cesselin F. (1988) Levels of MET-Enkephalin, LEU-Enkephalin, Substance P and Cholecystokinin in the Brain of the Common Marmoset Following Long Term 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Treatment.Neuropeptides 12, 105–110.

    PubMed  CAS  Google Scholar 

  • Tenovuo O., Rinne J. K., and Viljanen M. K. (1984) Substance P immunoreactivity in post-mortem parkinsonian brain.Brain Res. 303, 113–116.

    PubMed  CAS  Google Scholar 

  • Tenovuo O., Kolhinen A., Laihinen A., and Rinne U. K. (1990) Brain substance P receptors in Parkinson’s disease.Adv. Neurol. 53, 145–148.

    PubMed  CAS  Google Scholar 

  • Terry R. D., Masliah E., Salmon D., and DeTeresa H. (1990) Structure-function correlations in Alzheimer’s disease (abstract).J. Neuropathol. Exp. Neurol. 49, 318.

    Google Scholar 

  • Tomlinson B. E. (1989) The neuropathology of Alzheimer’s disease—issues in need of resolution.Neuropathol. Appl. Neurobiol. 15, 491–512.

    PubMed  CAS  Google Scholar 

  • Tomlinson B. E., Irving D., and Blessed G. (1981) Cell loss in the locus coeruleus in senile dementia of the Alzheimer type.J. Neurol. Sci. 49, 419–428.

    PubMed  CAS  Google Scholar 

  • Tomonoga M. (1983) Neuropathology of the locus coeruleus: A semiquantitative study.J. Neurol. 230, 231–240.

    Google Scholar 

  • Torack R. M. and Morris J. C. (1986) Mesocorticolimbical dementia.Arch. Neurol. 43, 1074–1078.

    PubMed  CAS  Google Scholar 

  • Torack R. M. and Morris J. C. (1988) The association of ventral tegmental area histopathology with adult dementia.Arch. Neurol. 45, 497–501.

    PubMed  CAS  Google Scholar 

  • Uhl G. R., Hedreen J. C., and Price D. L. (1985) Parkinson’s disease: Loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions.Neurology 35, 1215–1218.

    PubMed  CAS  Google Scholar 

  • Uhl G. R., McKinney M., Hedreen J. C., White C. L., Coyle J. T., Whitehouse P. J., and Price D. L. (1982) Dementia pugilistica: Loss of basal forebrain cholinergic neurons and cortical cholinergic markers.Ann. Neurol. 12, 99–102.

    Google Scholar 

  • Ulfig N. (1989) Altered lipofuscin pigmentation in the basal nucleus (Meynert) in Parkinson’s disease.Neurosci. Res. 6, 456–462.

    PubMed  CAS  Google Scholar 

  • Verity M. A. Roitberg B. and Kepes J. J. (1990) Mesolimbicocortical dementia: Clinico-pathological studies on two cases.J. Neurol. Neurosurg. Psychiatry 53, 492–495.

    PubMed  CAS  Google Scholar 

  • Vijayshankar N. and Brody H. (1979) A quantitative study of pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging.J. Neuropathol. Exp. Neurol. 38, 490–497.

    Google Scholar 

  • Vogels O. J. M., Broere C. A. J., and Nieuwenhuys R. (1990a) Neuronal hypertrophy in the human supraoptic and paraventricular nucleus in aging and Alzheimer’s disease.Neurosci. Lett. 109, 62–67.

    PubMed  CAS  Google Scholar 

  • Vogels O. J. M., Broere C. A. J., Ter Laak H. J., Ten Donkellar H. J., Nieuwenhuys R. and Schulte B. M. (1990b) Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer’s disease.Neurobiol. Aging 11, 3–13.

    PubMed  CAS  Google Scholar 

  • Wakabayashi K., Takahashi H., Takeda S., Ohama E., and Ikuta F. (1988) Parkinson’s disease: The presence of Lewy bodies in Auerbach’s and Meissner’s plexuses.Acta Neuropathol. (Berl.) 76, 217–221.

    CAS  Google Scholar 

  • Waters C. M., Peck P., Rossor M., Reynolds G. P., and Hunt S. P. (1988) Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson’s disease and Huntington’s chora.Neuroscience 25, 419–438.

    PubMed  CAS  Google Scholar 

  • Westlund K. N., Denney R. M., Kochersberger L. M., Rose R. M., and Abell C. W. (1985) Distinct monoamine oxidase A and B populations in primate brain.Science 230, 181–183.

    PubMed  CAS  Google Scholar 

  • Westlund K. N., Denney R. M., Rose R., and Abell C. M. (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem.Neuroscience 25, 439–456.

    PubMed  CAS  Google Scholar 

  • White O. B., Saint-Cyr J. A., Tomlinson R. D., and Sharpe J. A. (1983) Ocular motor deficits in Parkinson’s disease. I and II.Brain 106, 555–587.

    PubMed  Google Scholar 

  • Whitehouse P. J., Hedreen J. C., White C. L., and Price D. L. (1983) Basal forebrain neurons in the dementia of Parkinson’s disease.Ann. Neurol. 13, 243–248.

    PubMed  CAS  Google Scholar 

  • Whitehouse P. J., Vale W. W., Zweig R. M., Singer H. S., Mayeux R., Kuhar M. J., Price D. L., and DeSouza E. B. (1987) Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer’s disease, Parkinson’s disease and progressive supranuclear palsy.Neurology 37, 905–909.

    PubMed  CAS  Google Scholar 

  • Whitehouse P. J., Martino A. M., Wagster M. V., Price M. L., Mayeux R., Atack J. R., and Kellar K. J. (1988) Reductions in [3H]nicotinic acetylcholine binding in Alzheimer’s disease and Parkinson’s disease: An autoradiographic study.Neurology 38, 720–723.

    PubMed  CAS  Google Scholar 

  • Whitford C., Candy J., Edwardson J., and Perry J. (1988) Cortical somatostatinergic system not affected in Alzheimer’s and Parkinson’s diseases.J. Neurol. Sci. 86, 13–18.

    PubMed  CAS  Google Scholar 

  • Wilcock G. K., Esiri M. M., Bowen D., and Hughes A. O. (1988) The differential involvement of subcortical nuclei in senile dementia of the Alzheimer type.J. Neurol. Neurosurg. Psychiatry 51, 842–849.

    PubMed  CAS  Google Scholar 

  • Xuereb J. H., Perry E. K., Candy J. M., Bonham J. R., Perry R. H., and Marschall E. (1990) Parameters of cholinergic neurotransmission in the thalamus in Parkinson’s disease and Alzheimer’s disease.J. Neurol. Sci. 99, 185–197.

    PubMed  CAS  Google Scholar 

  • Yamada T., McGeer P. L., Baimbridge K. G., and McGeer E. G. (1990) Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbinding D 28K.Brain Res. 526, 303–307.

    PubMed  CAS  Google Scholar 

  • Yamamoto T. and Hirano A. (1985) Nucleus raphe dorsalis in Parkinson’s dementia complex of Guam.Acta Neuropathol. (Berl.) 67, 296–299.

    CAS  Google Scholar 

  • Yates C. M., Fink G. M., Bennie J. G., Gordon A., Simpson J., and Eskay R. L. (1984) Neurotensin immunoreactivity in post-mortem brain is increased in Down’s syndrome but not in Alzheimer-type dementia.J. Neurol. Sci. 67, 327–335.

    Google Scholar 

  • Zech M. and Bogerts B. (1985) Methionine, enkephalin and substance P in the basal ganglia of schizophrenics: A quantitative immunohistochemical comparison with Huntington and Parkinson patients.Acta Neuropathol. (Berl.) 68, 32–38.

    CAS  Google Scholar 

  • Zubenko G. S., Moossy J., and Kopp U. (1990) Neurochemical correlates of major depression in primary dementia.Arch. Neurol. 47, 209–214.

    PubMed  CAS  Google Scholar 

  • Zubenko G. S., Moossy J., Hanin I., Martinez A. J., Rao G. R., and Kopp G. R. (1988) Bilateral symmetry of cholinergic deficits in Alzheimer’s disease.Arch. Neurol. 45, 255–259.

    PubMed  CAS  Google Scholar 

  • Zweig R. M., Jankel W. R., Hedreen J. C., Mayeux R., and Price D. L. (1989a) The pedunculopontine nucleus in Parkinson’s disease.Ann. Neurol. 26, 41–46.

    PubMed  CAS  Google Scholar 

  • Zweig R. M., Rose C. A., Hedreen J. C., Steele C., Cardillo J. E., Whitehouse P. J., Folstein M. F., and Price D. L. (1988a) The neuropathology of aminergic nuclei in Alzheimer’s disease.Ann. Neurol. 24, 233–242.

    PubMed  CAS  Google Scholar 

  • Zweig R. M., Ross C. A., Peyser C., Cardillo J. E., Coehn M., Folstein S., and Price D. L. (1988b) The locus ceruleus and dementia in Parkinson’s disease and Huntington’s disease.Ann. Neurol. 24, 133.

    Google Scholar 

  • Zweig R. M., Ross C. A., Hedreen J. C., Steele C., Cardillo J. E., Whitehouse P. J., Folstein M. F., and Price D. L. (1989b) Neuropathology of aminergic nuclei in Alzheimer’s disease,Alzheimer’s disease and related disorders (Iqbal K., and Wisniewski H. M., eds.) pp. 353–365, A. R. Liss, New York.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jellinger, K.A. Pathology of Parkinson’s disease. Molecular and Chemical Neuropathology 14, 153–197 (1991). https://doi.org/10.1007/BF03159935

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03159935

Index Entries

Navigation